Showing results (51-60 of 78) with videos related to
Sort By:
Pageof 8
Molecular Therapy : the Journal of the American Society of Gene Therapy|August 9, 2012
Phase II trial of intravenous administration of Reolysin(®) (Reovirus Serotype-3-dearing Strain) in patients with metastatic melanomaEvanthia Galanis, Svetomir N Markovic, Vera J Suman, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 2008
Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study GroupDavid F McDermott, Jeffrey A Sosman, Rene Gonzalez, et al.Scientific Reports|April 15, 2025
LOXHD1 is an oncofusion-regulated antigen of ewing sarcomaTatiana Blanchard, Pouya Faridi, Chong Xu, et al.Journal for Immunotherapy of Cancer|May 17, 2020
Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trialSandra P D'Angelo, Shailender Bhatia, Andrew S Brohl, et al.Journal of Neuro-Oncology|August 16, 2011
Oligodendrogliomas in childrenKimberly M Creach, Joshua B Rubin, Jeffery R Leonard, et al.Proceedings of the National Academy of Sciences of the United States of America|November 6, 2019
Immunological ignorance is an enabling feature of the oligo-clonal T cell response to melanoma neoantigensGerald P Linette, Michelle Becker-Hapak, Zachary L Skidmore, et al.Nature Communications|July 17, 2021
Biochemical and functional characterization of mutant KRAS epitopes validates this oncoprotein for immunological targetingAdham S Bear, Tatiana Blanchard, Joseph Cesare, et al.The Journal of Clinical Investigation|September 17, 2024
Natural TCRs targeting KRASG12V display fine specificity and sensitivity to human solid tumorsAdham S Bear, Rebecca B Nadler, Mark H O'Hara, et al.Blood Advances|April 7, 2026
HLA-E single-chain trimer shields gene-edited allogeneic CAR T Cells from NK cell attackGerald P Linette, Kimberly Apodaca, Chong Xu, et al.The New England Journal of Medicine|April 21, 2015
Nivolumab and ipilimumab versus ipilimumab in untreated melanomaMichael A Postow, Jason Chesney, Anna C Pavlick, et al.Pageof 8